SG11201701674RA - Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same - Google Patents

Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Info

Publication number
SG11201701674RA
SG11201701674RA SG11201701674RA SG11201701674RA SG11201701674RA SG 11201701674R A SG11201701674R A SG 11201701674RA SG 11201701674R A SG11201701674R A SG 11201701674RA SG 11201701674R A SG11201701674R A SG 11201701674RA SG 11201701674R A SG11201701674R A SG 11201701674RA
Authority
SG
Singapore
Prior art keywords
same
hydroxycarbamoyl
benzofuran
carboxamide
phenoxy
Prior art date
Application number
SG11201701674RA
Inventor
Marina Gaillard
Philippe Letellier
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1458215A external-priority patent/FR3025196B1/en
Priority claimed from FR1458224A external-priority patent/FR3025197B1/en
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of SG11201701674RA publication Critical patent/SG11201701674RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
    • G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
    • G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Remote Sensing (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Geology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Geophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
SG11201701674RA 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same SG11201701674RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1458215A FR3025196B1 (en) 2014-09-03 2014-09-03 NOVEL 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE SALTS, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
FR1458224A FR3025197B1 (en) 2014-09-03 2014-09-03 NOVEL SALT OF 3 - [(DIMETHYLAMINO) METHYL] -N- {2- [4- (HYDROXYCARBAMOYL) PHENOXY] ETHYL} -1-BENZOFURAN-2-CARBOXAMIDE, ASSOCIATED CRYSTALLINE FORMS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF CONTAIN
PCT/US2015/048243 WO2016036910A1 (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
SG11201701674RA true SG11201701674RA (en) 2017-04-27

Family

ID=54186276

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701674RA SG11201701674RA (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
SG10201901916WA SG10201901916WA (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201901916WA SG10201901916WA (en) 2014-09-03 2015-09-03 Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Country Status (10)

Country Link
US (2) US20170266151A1 (en)
EP (1) EP3189040B1 (en)
JP (1) JP2017530106A (en)
KR (1) KR20170043648A (en)
CN (1) CN107001307A (en)
AU (1) AU2015311905B2 (en)
CA (1) CA2960044A1 (en)
MX (1) MX2017002858A (en)
SG (2) SG11201701674RA (en)
WO (1) WO2016036910A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701674RA (en) 2014-09-03 2017-04-27 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
EP4351734A1 (en) * 2021-06-10 2024-04-17 Teva Pharmaceuticals International GmbH Solid state forms of abexinostat and process for preparation thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
BRPI0409227C1 (en) * 2003-04-07 2021-05-25 Axys Pharm Inc compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (I)
CN100569753C (en) 2003-12-25 2009-12-16 卫材R&D管理有限公司 Crystallization (C) of the mesylate of 4-(3-chloro-4-(cyclopropyl aminocarboxyl) amino-benzene oxygen)-7-methoxyl group-6-quinolinecarboxamideas and preparation method thereof
US8702670B2 (en) 2004-06-30 2014-04-22 Mcneil-Ppc, Inc. Intravaginal device with controlled expansion
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
EP2480534A1 (en) 2009-09-24 2012-08-01 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
ES2842970T3 (en) * 2011-03-09 2021-07-15 Cereno Scient Ab Compounds and Methods for Ameliorating Altered Endogenous Fibrinolysis Using Histone Deacetylase Inhibitors
FR2977492B1 (en) 2011-07-04 2013-07-05 Servier Lab NOVEL ASSOCIATION BETWEEN N-HYDROXY-4- {2- [3- (N, N-DIMETHYLAMINOMETHYL) BENZOFURAN-2-YLCARBONYLAMINO] ETHOXY} BENZAMIDE AND FOLFOX
WO2013039956A2 (en) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
CN102531964B (en) * 2011-10-10 2014-06-11 华东理工大学 Dicarboxylic acid derivatives with anti-tumor effect and preparation method thereof
FR3002733B1 (en) 2013-03-04 2015-08-14 Servier Lab NOVEL SALT OF THE ABEXINOSTAT, THE CRYSTALLINE FORM ASSOCIATED WITH THEM, THE PROCESS FOR PREPARING THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SG11201701674RA (en) 2014-09-03 2017-04-27 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
US20200069637A1 (en) 2020-03-05
EP3189040A1 (en) 2017-07-12
EP3189040B1 (en) 2020-07-29
WO2016036910A1 (en) 2016-03-10
US10898461B2 (en) 2021-01-26
AU2015311905A1 (en) 2017-03-23
US20170266151A1 (en) 2017-09-21
CN107001307A (en) 2017-08-01
SG10201901916WA (en) 2019-04-29
JP2017530106A (en) 2017-10-12
KR20170043648A (en) 2017-04-21
AU2015311905B2 (en) 2020-03-05
CA2960044A1 (en) 2016-03-10
MX2017002858A (en) 2017-10-24

Similar Documents

Publication Publication Date Title
IL274488B1 (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
SI3097098T1 (en) Process for the preparation of n-((3-aminooxetan-3-yl)methyl)-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
EP3291814A4 (en) Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
HK1217487A1 (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction -2 n-[4-(2--12---4- )-]-
SG11201600996UA (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP3162793A4 (en) Chiral resolution method of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
PL3564208T3 (en) Method for preparing 2-(cyclohexenylene) malonic acid derivative and use thereof
IL272559B (en) Method for the preparation of 4-(heptafluoro-2-propyl) anilines
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
ZA202000224B (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
SI3292133T1 (en) Method for the preparation of 2-(4-(2-(((2-(4-chlorophenyl) -1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyan-6- (pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl-l-alanyl-l-alaninate hydrochloride
HUP1100351A2 (en) Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide
IL261135A (en) Process for preparing aminothiol ester compounds and salts thereof
HUP1400104A2 (en) Compositions comprising indometacine, its pharmaceutically acceptable salts and cocrystals; and process for the preparation
DK3164385T3 (en) NEW POLYMORPHIC FORM OF N- [2- (6-FLUORO-LH-INDOL-3-YL) ETHYL] -3- (2,2,3,3-TETRAFLUORPROPOXY) BENZYLAMINE HYDROCHLORIDE FOR THE TREATMENT OF ALZHEIMERS
IL257081A (en) A novel process for preparing crystalline methyl n-[2-[[[1-(4-chlorophenyl)-1h-pyrazol-3-yl]oxy]methyl]phenyl]-n-methoxycarbamate
ZA201603729B (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
HUP1400520A2 (en) Laquinimod salts useful for the preparation of pharmaceutical compositions
HUP1400103A2 (en) Compositions comprising nanostructured rosuvastatin, its pharmaceutically acceptable salts and cocrystals and process for the preparation
EP3153509A4 (en) N-(2-chloromethyl-1-methyl-1h-benzimidazole-5-acyl)-n-(pyridine-2-yl)-3-aminopropanoic acid ethyl ester preparation method
HUP1400519A2 (en) Crystalline form of laquinimod and sodium salt thereof useful for the preparation of pharmaceutical compositions